IL2 and acute myeloid leukemia: Furthermore, we found that the AML patient samples with the most profound proliferative defect (37% of those tested) had severely dysfunctional T cells with significantly decreased production of effector cytokines such as IFN-γ, IL-2, and TNF-α, and increased expression of inhibitory checkpoint markers such as CTLA-4.